Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of DOLUGRASE vs TIVICAY (dolutegravir 50 mg) in healthy adults under fasting conditions
TCTR20190826003Not yet recruiting
- Sponsor
- Government Pharmaceutical Organization
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of dolutegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Government Pharmaceutical Organization. Primary endpoint: Primary pharmacokinetic bioequivalence. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on TCTR20190826003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20190826003.